AP NEWS

Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor Pipeline Insight, 2018 Report - ResearchAndMarkets.com

November 30, 2018

DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

‘Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor

The report assesses the active Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report:

Provides a snapshot of the therapeutics pipeline activity for Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor Features the Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor

Key Topics Covered:

1. Report Introduction

2. Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor

4. Comparative Analysis

5. Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor Pipeline Products in Clinical Stages Product Description

Research and Development Product Development Activities

6. Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor Pipeline Products in Non-clinical Stages

Research and Development Product Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product Description Research and Development Product Development Activities Reason for dormancy/discontinuation

Companies Mentioned

Bayer Onyx Pharmaceuticals Array BioPharma Oncodesign Biotechnology Atriva Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/snsvxf/mitogen_activated?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005370/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Enzymes

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/30/2018 12:14 PM/DISC: 11/30/2018 12:14 PM

http://www.businesswire.com/news/home/20181130005370/en

AP RADIO
Update hourly